Findings from the phase 2 AVATAR trial suggest stereotactic ablative body radiotherapy may postpone the use of systemic therapy, offering patients with ER-positive/HER2-negative metastatic breast cancer another option.
November I, 2023
In a subgroup analysis of the phase 3 EMBARK study, enzalutamide alone or with leuprolide acetate improved metastatic-free survival in men with high-risk prostate cancer following radiotherapy.
As a monotherapy, bispecific antibodies have demonstrated antitumor activity in heavily pretreated patients with B-cell and T-cell hematologic malignancies, but much work is needed to determine the optimal setting.
The recent announcement of the 2023 Nobel Prize in Physiology or Medicine has turned attention again to RNA therapeutic vaccines and a better understanding of RNA biology.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
